These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35731023)

  • 21. Risk of metastatic pheochromocytoma and paraganglioma in
    Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
    J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.
    Park YG; Park I; Kim Y; Lee HS; Lee W; Yoon S; Lee JL
    Clin Genitourin Cancer; 2024 Apr; 22(2):413-419. PubMed ID: 38228412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolomic Urine Profile: Searching for New Biomarkers of SDHx-Associated Pheochromocytomas and Paragangliomas.
    Martins RG; Gonçalves LG; Cunha N; Bugalho MJ
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5467-5477. PubMed ID: 31504671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors.
    Xekouki P; Brennand A; Whitelaw B; Pacak K; Stratakis CA
    Horm Metab Res; 2019 Jul; 51(7):419-436. PubMed ID: 30273935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
    Vicha A; Taieb D; Pacak K
    Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
    Ferrara AM; Lombardi G; Pambuku A; Meringolo D; Bertorelle R; Nardin M; Schiavi F; Iacobone M; Opocher G; Zagonel V; Zovato S
    Anticancer Drugs; 2018 Jan; 29(1):102-105. PubMed ID: 29099418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
    Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
    Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma.
    Timmers HJ; Gimenez-Roqueplo AP; Mannelli M; Pacak K
    Endocr Relat Cancer; 2009 Jun; 16(2):391-400. PubMed ID: 19190077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
    Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
    Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paraganglioma and other tumour detection rates in individuals with SDHx pathogenic variants by age of diagnosis and after the age of 50.
    Greenberg SE; Holman R; Kohlmann W; Buchmann L; Naumer A
    Clin Endocrinol (Oxf); 2021 Sep; 95(3):447-452. PubMed ID: 34255389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
    Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
    Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
    Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.
    Matro J; Giubellino A; Pacak K
    Horm Metab Res; 2013 Feb; 45(2):147-53. PubMed ID: 23322515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.
    Buffet A; Burnichon N; Favier J; Gimenez-Roqueplo AP
    Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101416. PubMed ID: 32295730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
    Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice.
    Saie C; Buffet A; Abeillon J; Drui D; Leboulleux S; Bertherat J; Zenaty D; Storey C; Borson-Chazot F; Burnichon N; Vincent M; Favier J; Baudin E; Giraud S; Gimenez-Roqueplo AP; Amar L; Lussey-Lepoutre C
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1301-e1315. PubMed ID: 33247927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.
    Jawed I; Velarde M; Därr R; Wolf KI; Adams K; Venkatesan AM; Balasubramaniam S; Poruchynsky MS; Reynolds JC; Pacak K; Fojo T
    Cell Mol Neurobiol; 2018 Jul; 38(5):1099-1106. PubMed ID: 29623478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.
    Ricketts CJ; Forman JR; Rattenberry E; Bradshaw N; Lalloo F; Izatt L; Cole TR; Armstrong R; Kumar VK; Morrison PJ; Atkinson AB; Douglas F; Ball SG; Cook J; Srirangalingam U; Killick P; Kirby G; Aylwin S; Woodward ER; Evans DG; Hodgson SV; Murday V; Chew SL; Connell JM; Blundell TL; Macdonald F; Maher ER
    Hum Mutat; 2010 Jan; 31(1):41-51. PubMed ID: 19802898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update.
    Persu A; Lannoy N; Maiter D; Mendola A; Montigny P; Oriot P; Vinck W; Garin P; Hamoir M; Vikkula M
    Horm Metab Res; 2012 May; 44(5):349-53. PubMed ID: 22566194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.